Author and year of publication |
Country |
Study type |
Sample size (TDF-containing regimen) |
Comparison group |
Baseline duration on ART |
Follow-up duration |
Yazie et al. 2019 [17] |
Ethiopia |
Prospective observational study |
63 TDF + lamivudine + efavirenz OR TDF + lamivudine + ritonavir boosted atanzanavir |
- |
- |
6 months |
Agrawal et al. 2022 [18] |
India |
Non-randomized cross-sectional study |
50 TDF regime (tenofovir/lamivudine/efavirenz) |
50 non-TDF (ZLN, ZLA, ZLE) |
At least 1 year. (1 to 7 years) |
- |
Lee et al. 2019 [19] |
Korea |
Single-center retrospective cohort |
108 TDF-based regimen |
102 were ABC-based ART group |
- |
For ABC-based ART group 109.01 ± 26.96 weeks. For 79.68 ± 36.39 weeks for TDF |
Agbaji et al. 2019 [20] |
Nigeria |
Cohort |
TDF-exposed patients: 2,104 |
TDF-unexposed patients: 2,793 |
Naive at ART initiation |
144 weeks |
Tan et al. 2019 [21] |
China |
Single-center retrospective observational study |
269 patients on TDF + lamivudine +efavirenz |
- |
ART naïve |
baseline, 12, 24, 48, 96, 144, and168 weeks |
Hsu et al. 2020 [22] |
USA |
Cohort |
6,222 TDF-based regimen. Low risk: 4,743. Medium risk: 994. High risk: 484. The first composite exposure of interest consisted of TDF use (yes/no) and baseline DAD CKD risk group (low, medium, and high-risk). The second composite exposure consisted of TDF use (yes/no) and whether the ART regimen included a pharmacoenhancer (cobicistat or ritonavir, yes/no) standard ART regimen (two NRTIs and one core agent: non-boosted integrase strand transfer inhibitor, non-boosted nonnucleoside reverse transcriptase inhibitor (NNRTI), boosted elvitegravir, or boosted PI) |
3,580 non-TDF-based regimen. Low risk: 2,827. Medium risk: 481. High risk: 272. The no-TDF/low-risk group served as the referent group in comparative analyses. The no-TDF/non-boosted ART regimen group served as the referent group. in comparative analyses |
- |
24,382 person-years |
Yilma et al. 2020 [23] |
Ethiopia |
Cohort |
Naïve TDF, NNRTI regimen: 279 |
Non-TDF, NNRTI regimen: 60 |
- |
12 months |
Karoney et al. 2022 [24] |
Western Kenya |
Cross-sectional study |
TDF group: 261 |
Non-TDF group: 255 |
Median duration of ART: 6 years |
- |
Ng'umbi et al. 2022 [25] |
Uganda |
Hospital-based, cross-sectional study |
TDF-based regimen: 145 |
- |
24 ± 2 months |
Cross-sectional study |
Nishijima et al. 2018 [26] |
Japan |
Prospective cross-sectional study |
Current TDF users: 371. Past TDF users: 233 |
Never TDF users: 337 |
6 to 10 years |
Cross-sectional study |